Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» adagrasib
adagrasib
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Yahoo/Reuters
Tue, 12/6/22 - 10:21 am
Mirati Therapeutics
adagrasib
Merck
Keytruda
metastatic lung cancer
lung cancer
4 Biotech Stocks With Huge Incoming Catalysts
Motley Fool
Wed, 10/12/22 - 11:03 am
FDA
Biogen
Eisai
Alzheimer's disease
Gilead Sciences
HIV
Mirati Therapeutics
lung cancer
lecanemab
lenacapavir
adagrasib
ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says
Fierce Biotech
Mon, 06/6/22 - 10:33 am
ASCO 2022
Mirati Therapeutics
Amgen
Lumakras
adagrasib
lung cancer
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
BioPharma Dive
Fri, 05/27/22 - 10:15 am
Mirati Therapeutics
Amgen
KRAS
adagrasib
Lumakras
clinical trials
The biggest launches of 2022: a reboot
EP Vantage
Mon, 02/14/22 - 10:48 am
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach
Fierce Biotech
Fri, 10/8/21 - 10:34 am
Sanofi
Mirati Therapeutics
adagrasib
non-small cell lung cancer
Mirati fiddles as its share price burns
EP Vantage
Thu, 08/12/21 - 11:07 am
Mirati Therapeutics
Amgen
Lumakras
adagrasib
Closely Watched Mirati Reveals Results to Rival Amgen Drug
Bloomberg
Sun, 10/25/20 - 11:30 pm
Mirati Therapeutics
Amgen
adagrasib
lung cancer